Active Immunization of Patients With Head and Neck Squamous Cell Carcinoma (HNSCC) Using Fibroblasts Transfected With DNA From Autologous Tumor
Status: Withdrawn prior to enrolment
Phase of Trial: Phase I
Latest Information Update: 11 Sep 2017
Price : $35 *
At a glance
- Drugs IC 1002 (Primary)
- Indications Squamous cell cancer; Unspecified
- Focus Adverse reactions
- 31 Aug 2018 Biomarkers information updated
- 04 Sep 2017 Planned primary completion date changed from 1 Jul 2017 to 1 Oct 2017.
- 04 Sep 2017 Planned initiation date changed from 1 Apr 2015 to 1 Sep 2016.